Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ: CERO )

1.330 -0.090 (-6.34%)
Streaming Delayed Price Updated: 3:14 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 106,502
Open 1.430
Bid (Size) 1.350 (1)
Ask (Size) 1.430 (2)
Prev. Close 1.420
Today's Range 1.260 - 1.470
52wk Range 1.330 - 376.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-78.20%
-78.20%
1 Month
-30.73%
-30.73%
3 Month
-87.84%
-87.84%
6 Month
-86.67%
-86.67%
1 Year
-99.54%
-99.54%

More News

Read More
CERo Therapeutics Holdings, Inc. Highlights Progress
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Friday's after hours session: top gainers and losers
Via Chartmill
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Nasdaq Tumbles Over 200 Points; Alibaba Posts Upbeat Sales
Via Benzinga
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Why Domino's Pizza Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
CERo Therapeutics Stock Is Soaring Monday: What's Going On?
Via Benzinga
Nasdaq Moves Lower; Canaan Shares Surge
Via Benzinga
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Provides Corporate Update
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.